A Phase Ib/II study of Savolitinib in non-small cell lung cancer patients with c-Met mutations.
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Aug 2016 New trial record